Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Performance of magnetic resonance imaging in the diagnosis of axial spondyloarthritis: a systematic literature review.

Jones A, Bray TJP, Mandl P, Hall-Craggs MA, Marzo-Ortega H, Machado PM.

Rheumatology (Oxford). 2019 May 2. pii: kez172. doi: 10.1093/rheumatology/kez172. [Epub ahead of print]

PMID:
31046102
2.

Recommendations for acquisition and interpretation of MRI of the spine and sacroiliac joints in the diagnosis of axial spondyloarthritis in the UK.

Bray TJP, Jones A, Bennett AN, Conaghan PG, Grainger A, Hodgson R, Hutchinson C, Leandro M, Mandl P, McGonagle D, O'Connor P, Sengupta R, Thomas M, Toms A, Winn N, Hall-Craggs MA, Marzo-Ortega H, Machado PM; British Society of Spondyloarthritis (BRITSpA).

Rheumatology (Oxford). 2019 May 2. pii: kez173. doi: 10.1093/rheumatology/kez173. [Epub ahead of print]

PMID:
31046100
3.

Identification of myeloid cells in the human enthesis as the main source of local IL-23 production.

Bridgewood C, Watad A, Russell T, Palmer TM, Marzo-Ortega H, Khan A, Millner PA, Dunsmuir R, Rao A, Loughenbury P, Wittmann M, Cuthbert RJ, McGonagle DG.

Ann Rheum Dis. 2019 Jul;78(7):929-933. doi: 10.1136/annrheumdis-2018-214944. Epub 2019 Apr 24.

4.

Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease: reply.

Dubash S, Marzo-Ortega H, McGonagle D.

Rheumatology (Oxford). 2019 Jun 1;58(6):1115-1117. doi: 10.1093/rheumatology/kez053. No abstract available.

PMID:
30847468
5.

Association of Diverticulitis with Prolonged Spondyloarthritis: An Analysis of the ASAS-COMOSPA International Cohort.

Derakhshan MH, Goodson NJ, Packham J, Sengupta R, Molto A, Marzo-Ortega H, Siebert S; BRITSpA and the ASAS-COMOSPA Investigators.

J Clin Med. 2019 Feb 26;8(3). pii: E281. doi: 10.3390/jcm8030281.

6.

A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service.

Abignano G, Fadl N, Merashli M, Vandevelde C, Freeston J, McGonagle D, Marzo-Ortega H.

J Am Acad Dermatol. 2019 Jun;80(6):1796-1798. doi: 10.1016/j.jaad.2019.02.014. Epub 2019 Feb 13. No abstract available.

PMID:
30771422
7.

Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.

Gladman DD, Orbai AM, Klitz U, Wei JC, Gallo G, Birt J, Rathmann S, Shrom D, Marzo-Ortega H.

Arthritis Res Ther. 2019 Jan 29;21(1):38. doi: 10.1186/s13075-019-1831-0.

8.

Increased Risk of Hypertension Associated with Spondyloarthritis Disease Duration: Results from the ASAS-COMOSPA Study.

Derakhshan MH, Goodson NJ, Packham JC, Sengupta R, Molto A, Marzo-Ortega H, Siebert S; BRITSpA and COMOSPA Investigators.

J Rheumatol. 2019 Jan 15. pii: jrheum.180538. doi: 10.3899/jrheum.180538. [Epub ahead of print]

PMID:
30647169
9.

The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.

Dubash S, Bridgewood C, McGonagle D, Marzo-Ortega H.

Expert Rev Clin Immunol. 2019 Feb;15(2):123-134. doi: 10.1080/1744666X.2019.1561281. Epub 2019 Jan 8.

PMID:
30576610
10.

Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.

Kavanaugh A, Marzo-Ortega H, Vender R, Wei CC, Birt J, Adams DH, Benichou O, Lin CY, Nash P.

Clin Exp Rheumatol. 2018 Nov 19. [Epub ahead of print]

PMID:
30557128
11.

The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science.

Watad A, Bridgewood C, Russell T, Marzo-Ortega H, Cuthbert R, McGonagle D.

Front Immunol. 2018 Nov 16;9:2668. doi: 10.3389/fimmu.2018.02668. eCollection 2018. Review.

12.

Defining the target: clinical aims in axial spondyloarthritis.

Marzo-Ortega H, Gaffney KM, Gaffney K.

Rheumatology (Oxford). 2018 Aug 1;57(suppl_6):vi18-vi22. doi: 10.1093/rheumatology/key176.

13.

Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis.

Abignano G, Laws P, Del Galdo F, Marzo-Ortega H, McGonagle D.

Clin Exp Dermatol. 2019 Jun;44(4):462-465. doi: 10.1111/ced.13786. Epub 2018 Sep 23. No abstract available.

PMID:
30246363
14.

The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis.

Garcia-Montoya L, Marzo-Ortega H.

Ther Adv Musculoskelet Dis. 2018 Sep 6;10(9):169-180. doi: 10.1177/1759720X18787766. eCollection 2018 Sep. Review.

15.

Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.

Dubash S, Marianayagam T, Tinazzi I, Al-Araimi T, Pagnoux C, Weizman AV, Richette P, Tran Minh ML, Allez M, Singh A, Ciccia F, Hamlin J, Tan AL, Marzo-Ortega H, McGonagle D.

Rheumatology (Oxford). 2019 Jun 1;58(6):963-968. doi: 10.1093/rheumatology/key267.

PMID:
30204909
16.

Assessment of SpondyloArthritis International Society (ASAS) Consensus on Spanish Nomenclature for Spondyloarthritis.

Navarro-Compán V, Otón T, Loza E, Almodóvar R, Ariza-Ariza R, Bautista-Molano W, Burgos-Vargas R, Collantes-Estévez E, de Miguel E, González-Fernández C, Gratacós J, Ibáñez S, Juanola X, Maldonado-Cocco J, Moltó A, Mulero J, Pacheco-Tena C, Ramos-Remus C, Sanz-Sanz J, Valle-Oñate R, Zarco P, Marzo-Ortega H.

Reumatol Clin. 2018 Sep 4. pii: S1699-258X(18)30173-6. doi: 10.1016/j.reuma.2018.07.014. [Epub ahead of print] English, Spanish.

17.

Acute Unilateral Sacroiliitis Mimicking Infection on Magnetic Resonance Imaging with Response to Nonsteroidal Antiinflammatory Drugs: A Distinct Presentation of Spondyloarthritis?

Dubash S, Pease C, Aslam A, Coady D, McGONAGLE D, Marzo-Ortega H.

J Rheumatol. 2018 Dec;45(12):1708-1710. doi: 10.3899/jrheum.171456. Epub 2018 Aug 15. No abstract available.

PMID:
30111637
18.

Combined inhibition of tumour necrosis factor-alpha and interleukin-12/23 for long-standing, refractory psoriatic disease: a differential role for cytokine pathways?

De Marco G, McGonagle D, Mathieson HR, Merashli M, Magee C, FitzGerald O, Goodfield M, Marzo-Ortega H.

Rheumatology (Oxford). 2018 Nov 1;57(11):2053-2055. doi: 10.1093/rheumatology/key199. No abstract available.

PMID:
29982709
19.

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.

Landewé R, Sieper J, Mease P, Inman RD, Lambert RG, Deodhar A, Marzo-Ortega H, Magrey M, Kiltz U, Wang X, Li M, Zhong S, Mostafa NM, Lertratanakul A, Pangan AL, Anderson JK.

Lancet. 2018 Jul 14;392(10142):134-144. doi: 10.1016/S0140-6736(18)31362-X. Epub 2018 Jun 29.

PMID:
29961640
20.

Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.

Kiltz U, van der Heijde D, Boonen A, Akkoc N, Bautista-Molano W, Burgos-Vargas R, Wei JC, Chiowchanwisawakit P, Dougados M, Duruoz MT, Elzorkany BK, Gaydukova I, Gensler LS, Gilio M, Grazio S, Gu J, Inman RD, Kim TJ, Navarro-Compan V, Marzo-Ortega H, Ozgocmen S, Pimentel Dos Santos F, Schirmer M, Stebbings S, Van den Bosch FE, van Tubergen A, Braun J.

Ann Rheum Dis. 2018 Sep;77(9):1311-1317. doi: 10.1136/annrheumdis-2017-212076. Epub 2018 Jun 1.

21.

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.

Emery P, Van Keep M, Beard S, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H.

Pharmacoeconomics. 2018 Aug;36(8):1015-1027. doi: 10.1007/s40273-018-0675-9.

22.

MRI of psoriatic nail disease pre- and post-TNF inhibitor therapy shows persistent subclinical inflammation after 6 months despite good clinical response.

Ash Z, Tan AL, Hodgson RJ, Grainger A, Marzo-Ortega H, McGonagle DG.

RMD Open. 2018 Feb 2;4(1):e000599. doi: 10.1136/rmdopen-2017-000599. eCollection 2018. No abstract available.

23.

New advances in the understanding and treatment of axial spondyloarthritis: from chance to choice.

Dubash S, McGonagle D, Marzo-Ortega H.

Ther Adv Chronic Dis. 2018 Mar;9(3):77-87. doi: 10.1177/2040622317743486. Epub 2017 Dec 14. Review.

24.

Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.

Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H.

RMD Open. 2017 Dec 28;3(2):e000592. doi: 10.1136/rmdopen-2017-000592. eCollection 2017.

25.

Apremilast for the treatment of active psoriatic arthritis: a single-centre real-life experience.

Abignano G, Fadl N, Merashli M, Wenham C, Freeston J, McGonagle D, Marzo-Ortega H.

Rheumatology (Oxford). 2018 Mar 1;57(3):578-580. doi: 10.1093/rheumatology/kex454. No abstract available.

26.

Short-term Repeat Magnetic Resonance Imaging Scans in Suspected Early Axial Spondyloarthritis Are Clinically Relevant Only in HLA-B27-positive Male Subjects.

Sengupta R, Marzo-Ortega H, McGonagle D, Wadeley A, Bennett AN; British Society for Spondyloarthritis.

J Rheumatol. 2018 Feb;45(2):202-205. doi: 10.3899/jrheum.170171. Epub 2017 Dec 1.

PMID:
29196379
27.

Serum IL-7 as diagnostic biomarker for rheumatoid arthritis, validation with EULAR 2010 classification criteria.

Burska AN, Neilan J, Chisman RE, Pitaksalee R, Hodgett R, Marzo-Ortega H, Conaghan PG, West R, Emery P, Ponchel F.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):115-120. Epub 2017 Sep 15.

PMID:
28980908
28.

Limited reliability of radiographic assessment of spinal progression in ankylosing spondylitis.

Aydin SZ, Kasapoglu Gunal E, Kurum E, Akar S, Mungan HE, Alibaz-Oner F, Lambert RG, Atagunduz P, Marzo Ortega H, McGonagle D, Maksymowych WP.

Rheumatology (Oxford). 2017 Dec 1;56(12):2162-2169. doi: 10.1093/rheumatology/kex321.

PMID:
28968836
29.

Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis.

Bowes J, Ashcroft J, Dand N, Jalali-Najafabadi F, Bellou E, Ho P, Marzo-Ortega H, Helliwell PS, Feletar M, Ryan AW, Kane DJ, Korendowych E, Simpson MA, Packham J, McManus R, Brown MA, Smith CH, Barker JN, McHugh N, FitzGerald O, Warren RB, Barton A.

Ann Rheum Dis. 2017 Oct;76(10):1774-1779. doi: 10.1136/annrheumdis-2017-211414. Epub 2017 Aug 18.

30.

Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project.

López-Medina C, Jiménez-Gómez Y, Moltó A, Schiotis RE, Marzo-Ortega H, van Gaalen FA, Ozgocmen S, Dougados M, Calvo-Gutiérrez J, Castro-Villegas MC, Collantes-Estévez E, Font-Ugalde P; ASAS-COMOSPA task force.

Joint Bone Spine. 2018 Jul;85(4):447-453. doi: 10.1016/j.jbspin.2017.07.006. Epub 2017 Jul 25.

31.
32.

Vascularity of nail bed by ultrasound to discriminate psoriasis, psoriatic arthritis and healthy controls.

Aydin SZ, Castillo-Gallego C, Ash ZR, Marzo-Ortega H, Wakefield R, McGonagle D.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):872. Epub 2017 Jun 16. No abstract available.

PMID:
28628470
33.

Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis.

Cuthbert RJ, Fragkakis EM, Dunsmuir R, Li Z, Coles M, Marzo-Ortega H, Giannoudis PV, Jones E, El-Sherbiny YM, McGonagle D.

Arthritis Rheumatol. 2017 Sep;69(9):1816-1822. doi: 10.1002/art.40150. Epub 2017 Aug 8.

34.

The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia.

Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H, McGonagle DG.

Rheumatology (Oxford). 2018 Jan 1;57(1):32-40. doi: 10.1093/rheumatology/kex079. Review.

35.

The Use of Magnetic Resonance Imaging in Axial Spondyloarthritis: Time to Bridge the Gap Between Radiologists and Rheumatologists.

Bennett AN, Marzo-Ortega H, Kaur-Papadakis D, Rehman A; BRITSpA.

J Rheumatol. 2017 Jun;44(6):780-785. doi: 10.3899/jrheum.161337. Epub 2017 Apr 1.

36.

Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.

Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B; Measure 2 Study Group.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-1029. doi: 10.1002/acr.23233. Epub 2017 Jun 7.

37.

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.

van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Géher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compàn V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J.

Ann Rheum Dis. 2017 Jun;76(6):978-991. doi: 10.1136/annrheumdis-2016-210770. Epub 2017 Jan 13. Review.

PMID:
28087505
38.

Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?

Keat A, Bennett AN, Gaffney K, Marzo-Ortega H, Sengupta R, Everiss T.

Rheumatol Int. 2017 Mar;37(3):327-336. doi: 10.1007/s00296-016-3635-8. Epub 2016 Dec 29. Review.

PMID:
28035438
39.

Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages.

Kiltz U, van der Heijde D, Boonen A, Bautista-Molano W, Burgos-Vargas R, Chiowchanwisawakit P, Duruoz T, El-Zorkany B, Essers I, Gaydukova I, Géher P, Gossec L, Grazio S, Gu J, Khan MA, Kim TJ, Maksymowych WP, Marzo-Ortega H, Navarro-Compán V, Olivieri I, Patrikos D, Pimentel-Santos FM, Schirmer M, van den Bosch F, Weber U, Zochling J, Braun J.

RMD Open. 2016 Oct 4;2(2):e000311. eCollection 2016.

40.

Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.

Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB; MEASURE 2 Study Group.

Ann Rheum Dis. 2017 Mar;76(3):571-592. doi: 10.1136/annrheumdis-2016-210023. Epub 2016 Aug 31.

PMID:
27582421
41.

BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.

Hamilton L, Barkham N, Bhalla A, Brittain R, Cook D, Jones G, Mackay K, Marshall D, Marzo-Ortega H, Murphy D, Riddell C, Sengupta R, Siebert S, Van Rossen L, Gaffney K; BSR and BHPR Standards, Guidelines and Audit Working Group.

Rheumatology (Oxford). 2017 Feb;56(2):313-316. doi: 10.1093/rheumatology/kew223. Epub 2016 Aug 24. No abstract available.

PMID:
27558584
42.

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.

Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, Marzo-Ortega H, Feist E, Shah K, Hu C, Stevens RM, Poder A.

J Rheumatol. 2016 Sep;43(9):1724-34. doi: 10.3899/jrheum.151376. Epub 2016 Jul 15.

PMID:
27422893
43.

Poor awareness of inflammatory back pain and axial spondyloarthritis among secondary care specialists.

Mathieson HR, Merashli M, Gaffney K, Marzo-Ortega H; BRITSpA (British Society for Spondyloarthritis).

Clin Rheumatol. 2016 Oct;35(10):2627-8. doi: 10.1007/s10067-016-3305-y. Epub 2016 May 14. No abstract available.

PMID:
27180070
44.

Evidence of response to IL-6 inhibition in some cases of refractory spondyloarthritis-associated peripheral synovitis.

Merashli M, De Marco G, Podgorski M, McGonagle D, Marzo-Ortega H.

Ann Rheum Dis. 2016 Jul;75(7):1418-20. doi: 10.1136/annrheumdis-2016-209275. Epub 2016 Apr 8. No abstract available.

45.

The role of biomechanical factors in ankylosing spondylitis: the patient's perspective.

Ansell RC, Shuto T, Busquets-Perez N, Hensor EM, Marzo-Ortega H, McGonagle D.

Reumatismo. 2015 Dec 30;67(3):91-6. doi: 10.4081/reumatismo.2015.853.

46.

Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.

Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Ozgocmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M; ASAS.

Ann Rheum Dis. 2016 Jun;75(6):1034-42. doi: 10.1136/annrheumdis-2015-208730. Epub 2016 Feb 10.

PMID:
26865599
47.

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.

Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, Moe-Byrne T, Fox D, Marzo-Ortega H, Kay L, Woolacott N, Palmer S.

Health Technol Assess. 2016 Feb;20(9):1-334, v-vi. doi: 10.3310/hta20090. Review.

48.

Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis.

Smith RL, Hébert HL, Massey J, Bowes J, Marzo-Ortega H, Ho P, McHugh NJ, Worthington J, Barton A, Griffiths CE, Warren RB.

Arch Dermatol Res. 2016 Apr;308(3):201-5. doi: 10.1007/s00403-016-1620-4. Epub 2016 Feb 1.

49.

Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.

Rudwaleit M, Rosenbaum JT, Landewé R, Marzo-Ortega H, Sieper J, van der Heijde D, Davies O, Bartz H, Hoepken B, Nurminen T, Deodhar A.

Arthritis Care Res (Hoboken). 2016 Jun;68(6):838-44. doi: 10.1002/acr.22848.

50.

Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.

Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KG, Sieper J, Baraliakos X, Bennett A, Braun J, Burgos-Vargas R, Dougados M, Pedersen SJ, Jurik AG, Maksymowych WP, Marzo-Ortega H, Østergaard M, Poddubnyy D, Reijnierse M, van den Bosch F, van der Horst-Bruinsma I, Landewé R.

Ann Rheum Dis. 2016 Nov;75(11):1958-1963. doi: 10.1136/annrheumdis-2015-208642. Epub 2016 Jan 14. Review.

PMID:
26768408

Supplemental Content

Loading ...
Support Center